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Previewsbetter define the role of classical, interme-
diate, and nonclassical monocytes in
thesemodels, potentially identifying novel
targets for therapy.
Over the recent years, an increasing
amount of knowledge has been gained
in the field of monocyte subpopulations.
Although there is still much to be learned,
the study of Cros et al. brings us one step
closer to a better understanding of mono-
cytes in health and disease, which poten-
tially paves the way for developing new
immunomodulatory therapies.
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In this issue of Immunity, Omatsu et al. (2010) provide new information on the CXCL12 abundant reticular
(CAR) cells that support hematopoietic stem cells and lymphoid progenitors in bone marrow. CAR cells
can convert to adipocytes and osteoblasts, additional cells known to regulate hematopoiesis.Hematopoietic stem cells (HSCs) sustain
blood formation throughout life and
their integrity depends on residence in
specialized niches within bone marrow.
However, there are considerable tech-
nical problems associated with sectioning
lipid-rich, bone-encapsulated tissue while
preserving distinctive niche markers and
unambiguously identifying HSCs. For
those and other reasons, precise informa-
tion about the cellular and molecular
composition of those niches has been
difficult to obtain. Fortunately, those
hurdles have been overcome, and a new
picture is emerging about how the factory
that marrow represents can adapt to
circumstances.
The CXCL12 chemokine (also known as
SDF-1) is essential for the initial coloniza-
tion, retention, and support of HSCs andearly B lymphocyte lineage cells in bone
marrow. Identification of CXCL12 abun-
dant reticular (CAR) cells as a major
source of this factor was previously
achieved with CXCL12-GFP (green fluo-
rescent protein) knockin mice (Sugiyama
et al., 2006). CAR cells are scattered in
the extravascular regions of marrow,
with some near the endosteum and others
surrounding venous sinusoids (Figure 1).
HSCs and some, but not all, lymphoid
progenitors physically associate with
CAR cells. Omatsu et al. (2010) now
obtain new information about their func-
tion with CXCL12-DTR (diphtheria toxin
receptor)-GFP knockin animals. Although
GFP+ CAR cells can be imaged when the
mice are untreated, they are effectively
depleted within 2 days of injection of dip-
theria toxin (DT). Control chimeric mouseexperiments showed that hematopoietic
cells are not directly affected by DT.
Importantly, numbers of spindle-shaped
N-cadherin+ CD45 osteoblastic cells
and sinusoidal endothelial cells were not
reduced. HSCs have previously been
shown to physically associate with both
of these two cell types (Zhang and Li,
2008; Kiel and Morrison, 2008).
Selective CAR cell ablation caused an
approximate 50% reduction in HSC
numbers and much greater depletion of
hematopoietic progenitors. Although it is
unclear whether that resulted frommobili-
zation out of themarrow, HSCs retained in
that site had unique properties. That is,
they were smaller in size and had reduced
RNA and less cell cycle promoting gene
expression. This suggests that they were
even more quiescent than is typical forptember 24, 2010 ª2010 Elsevier Inc. 291
Figure 1. Chemokine-Producing Cells Are Multipotential and Essential to Hematopoiesis
CXCL12 abundant reticular (CAR) cells are also a major source of stem cell factor. Characterized as
VCAM-1+CD45TER119CD51+PDGFRa+PDGFRb+SCA-1, CAR cells are present in close proximity
to hematopoietic stem cells (HSCs) in several sites. Selective depletion in a new animal model reduced
HSC numbers, leaving behind HSCs that were exceptionally quiescent and myeloid skewed. Lymphoid
progenitors known to be dependent on CXCL12 and megakaryocyte-erythroid progenitors were even
more depleted (not illustrated). CAR cells are primed to generate osteoblastic cells that might nurture
HSCs, as well as adipocytes that can suppress hematopoiesis.
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extended residence in a quiescent, nondi-
viding state is essential for maintenance
of HSC functions. The new findings
seem incompatible with earlier studies
suggesting that CXCL12 can be a quies-
cence promoting factor (Sugiyama et al.,
2006). However, HSC changes might
have resulted from reduced access to
stem cell factor as well as CXCL12, inas-
much as CAR cells are a major source of
both substances. Small, quiescent HSCs
were survivors in short-term cultures con-
taining only fetal calf serum, indicating
that this is a default state in the absence
of growth and differentiation factors.
The selectivity of HSC dependence on
CAR cells is interesting within the context
of recent papers describing intrinsic
HSC heterogeneity (Ichii et al., 2010). For
example, some HSCs are skewed toward
myeloid cell production. In the study by
Omatsu et al. (2010), HSCs unable to
interact with CAR cells upregulated
macrophage colony-stimulating factor
receptor and PU.1 transcription factor
transcripts associated with myelopoiesis.
Myeloid cell potential revealed by culture
was also increased. In contrast, CXCL12
was originally discovered in connection
with B lymphopoiesis and cells in that
lineage were quickly depleted with CAR
cell ablation. Thus, HSCs remaining
in CAR cell-deficient mice could be
those with little potential to restore the
immune system. Subsets of HSCs can292 Immunity 33, September 24, 2010 ª2010undergo an extended period of hiberna-
tion, and some of them generate blood
cells after only two cycles of transplanta-
tion. Again, those might be relatively
independent of CXCL12. It is probable
that gradients of CXCL12 exist in bone
marrow. Proximity to CAR cells could
influence lineage choice decisions as
well as HSC cycling.
Monoclonal antibodies are being devel-
oped that resolve HSC subsets and many
are already appropriate for identifying
hematopoietic progenitors (Morita et al.,
2010). Thus, it should be possible to
understand more about the topography
of functionally specialized hematopoietic
cells and stromal elements they are sup-
ported by.
VCAM-1+CD45TER119 CAR cells
were additionally shown to be CD51+,
PDGFRa+, PDGFRb+, and SCA-1. Infor-
mation of that kind should be useful for
identifying CAR cells in mice that lack
knockin reporter constructs. They were
found to express transcripts for Runx2
and osterix, transcription factors associ-
ated with bone formation. Furthermore,
culture of whole marrow in bone morpho-
genetic protein-2 favored formation of
CAR cells expressing the osteoblast
marker alkaline phosphatase. As another
possible indication of relatedness, bone-
lining osteoblasts express low amounts
of CXCL12 (Sugiyama et al., 2006).
In young mice, some CAR cells were
physically associated with bone-liningElsevier Inc.cells. Experimental manipulations involv-
ing osteoblast-like cells have shown that
they can regulate numbers and integrity
of HSCs (Zhang and Li, 2008; Kiel and
Morrison, 2008).
CAR cells also contained abundant
transcripts for C/EBPa and peroxisome
proliferator-activated receptor g, proteins
associated with adipogenesis. Culture of
marrow with the PPARg activator piaglita-
zone promoted formation of lipid-laden
CAR cells. CAR cells with adipocyte char-
acteristics were more conspicuous in
marrow of mice myeloablated with 5-fluo-
rouracil treatment. Adipocytes function
as negative regulators of hematopoiesis
within bone marrow (Naveiras et al.,
2009). Thus, alterations in CAR cells could
tip the balance in favor of support or
suppression of blood cell formation.
Multipotent stromal cells, often referred
to as mesenchymal stem cells (MSCs),
are capable of generating osteoblasts,
chondrocytes, adipocytes, fibroblasts,
and advential reticular cells (Bianco
et al., 2008). We now learn that this family
of cell types includes CAR cells. That is,
they share some properties and are
at least convertible under experimental
conditions. It would be nice to know
whether long-term depletion of CAR
cells compromises numbers of adipo-
cytes and osteoblasts inasmuch as it
would be informative about precursor-
product relationships between the three
cell types. Experimental depletion or
expansion of any one of these compo-
nents of the marrow environment might
influence numbers and function of the
others. Unfortunately, CXCL12-DTR-GFP
knockinmice die within 5 days of DT injec-
tion with evidence of liver damage.
The new observations are similar in
many respects to those in another recent
report, where MSCs were identified and
manipulated on the basis of nestin
expression (Me´ndez-Ferrer et al., 2010).
For example, CXCL12 transcripts were
high in nestin+ MSCs and their depletion
reduced numbers of HSCs approximately
50%. As another similarity, these MSCs
also had potential for osteogenic and
adipogenic differentiation. It will be inter-
esting to know whether these populations
completely overlap. The combined infor-
mation about CAR cells and nestin+
MSCs represents a substantial advance
in understanding hematopoietic microen-
vironments.
Immunity
PreviewsIt seems likely that additional cells and
molecules contribute to the support of
HSCs and progenitor cells. For example,
marrow failure results from targeting
the gp130 cytokine receptor component
on endothelial cells (Yao et al., 2005).
Regardless, the new findings suggest
how specialized subsets of multipotent
stromal cells are developmentally related
and perhaps functionally linked. Endo-
crine and neural signals presumably
convert them to cell types that maintain
stem cell integrity, influence lineage
choice decisions, or suppress hemato-
poiesis.REFERENCES
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In this issue of Immunity, Pe´rez de Diego et al. (2010) report a primary human immune deficiency involving
a TRAF protein and show that human immunity to the virus HSV-1 is critically dependent on TRAF3.Tumor necrosis factor (TNF) receptor
associated factors (TRAFs) are multifunc-
tional intracellular proteins that recruit
and activate protein kinases in immune
signaling pathways. The function of
many TRAF proteins has been particularly
well established in TNF receptor family
signaling in B and T lymphocytes and in
pattern recognition receptor (PRR) sig-
naling in antigen-presenting cells, mainly
through the use of gene-deleted mice.
For example, TRAF6 has been shown to
be critical for signaling by two PRR fami-
lies, namely the Toll-like receptors (TLRs)
and RIG-I-like receptors (RLRs), where it
controls activation of the transcription
factor NF-kB, leading to the production
of proinflammatory cytokines. However,
the function of TRAF3 remained enigmatic
until 2006 because Traf3/ mice die
shortly after birth (Xu et al., 1996). In that
year, two studies used Traf3/ myeloid
cells to show that TRAF3 was essential
for induction of type I interferons (IFNs)in response to all the murine antiviral
nucleic acid sensing TLRs (TLR3, -7, -9)
and also for TLR-independent type I IFN
induction, whereas in contrast to TRAF6,
there was no positive role for TRAF3
in NF-kB activation (Oganesyan et al.,
2006; Ha¨cker et al., 2006). For TLRs,
TRAF3 acted downstream of the TLR
signaling proteins TRIF (for TLR3) and
MyD88 and IRAK-4 (for TLR7 and -9),
whereas TRAF3 acted in the RLRpathway
downstream of the adaptor MAVS (Saha
et al., 2006). Murine TRAF3 was also
shown to negatively regulate the nonca-
nonical NF-kB pathway in B cells, which
involves processing of NF-kB p100 into
NF-kB p52, and indeed, constitutive acti-
vation of this pathway explained the post-
natal lethality seen in Traf3/ mice (He
et al., 2006). Thus, in mice, using Traf3/
cells, TRAF3 was assigned a positive role
in type I IFN induction by PRRs and
a negative regulatory role in B cells.
However, the role of TRAF3 in hostdefense in vivo and in immunity to infec-
tion was untested because of the lack
of viable Traf3/ mice. Furthermore,
nothing was known about the role of
TRAF3 (or indeed any TRAF) in human
host defense.
In this issue of Immunity, Pe´rez de
Diego et al. (2010) now provide insight
into the immunological role of TRAF3 in
host defense in vivo. Moreover, they do
so in the human system, because they
describe TRAF3 deficiency as a genetic
susceptibility to herpes simplex virus-1
(HSV-1) encephalitis (HSE), a severe
infection of the human central nervous
system (CNS). Not only does this study
provide real evidence for a role for
TRAF3 in human immune responses, it
also represents a demonstration of a
primary immune deficiency involving a
TRAF protein. Evidence is presented
for an autosomal dominant TRAF3 defi-
ciency in a young adult with a history of
HSE in childhood in that a single pointptember 24, 2010 ª2010 Elsevier Inc. 293
